Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation

Elmariah, Hany; Brunstein, Claudio G.; Bejanyan, Nelli

doi:10.3390/life11020102

Cited by 12 publications

(7 citation statements)

References 135 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relapse is the main cause of treatment failure and its prognosis is poor (18) . Malignant cells can escape the cytotoxic lesion associated with the pre-transplant conditioning regime and the immune control created by the medullary and immune reconstitution in the posttransplant and cause disease relapse which does not respond to the chemotherapeutic drugs previously used, requiring a more cytotoxic drug arsenal (19) .…”

Section: Discussionmentioning

confidence: 99%

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Azevedo,

Ferreira Júnior,

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Objective: to analyze the factors associated with the failure of Hematopoietic Stem Cell Transplantation (HSCT) in patients undergoing Hematopoietic Stem Cell Retransplantation (HSCR). Method: this study implemented a quantitative approach and was a case-control type which addressed patients undergoing HSCR. To do so, a paired sample of two controls was used for each case (2:1). The case group consisted of the medical records of all patients who underwent HSCR (28) and the control group (56) of those who underwent only one transplant. Three variables guided the pairing: gender, diagnosis and type of transplant. Results: a total of 24 (85.71%) patients in the case group were re-transplanted due to disease relapse and four (14.29%) due to graft failure. There was a statistical difference in the analysis between patients who did not use ursodeoxycholic acid, opioid analgesics and immunosuppressants. The need for HSCR among those who used these medications inappropriately was 16.12, 12.79 and 4.5 times more likely, respectively, than those who used them correctly. Conclusion: there was a difference regarding the reasons which led to the retransplantation and the analyzed subjects, and this study concluded that the predictive reason for retransplantation in the studied sample was disease relapse.

show abstract

Section: Discussionmentioning

confidence: 99%

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Azevedo,

Ferreira Júnior,

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

show abstract

“…Relapse is the main cause of treatment failure and its prognosis is poor 18 . Malignant cells can escape the cytotoxic lesion associated with the pre-transplant conditioning regime and the immune control created by the medullary and immune reconstitution in the post-transplant and cause disease relapse which does not respond to the chemotherapeutic drugs previously used, requiring a more cytotoxic drug arsenal 19 .…”

Section: Discussionmentioning

confidence: 99%

Análise dos fatores associados ao retransplante de células-tronco hematopoiéticas: estudo caso-controle

Azevedo

Júnior

Nascimento

et al. 2022

Rev. Latino-Am. Enfermagem

View full text Add to dashboard Cite

Resumo Objetivo: analisar os fatores associados ao insucesso do Transplante de Células-Tronco Hematopoiéticas (TCTH) em pacientes submetidos ao retransplante de Células-Tronco Hematopoiéticas (RCTH). Método: estudo quantitativo do tipo caso-controle para avaliar pacientes submetidos ao RCTH. Para tanto, utilizou-se amostra pareada de dois controles para cada caso (2:1). O grupo caso foi constituído pelos prontuários de saúde com todos os pacientes que foram submetidos ao RCTH (28) e o grupo controle (56) incluiu pacientes que receberam apenas um transplante. Três variáveis nortearam o pareamento: sexo, diagnóstico e tipo de transplante. Resultados: vinte e quatro (85,71%) pacientes do grupo caso receberam retransplante devido a recidiva da doença e quatro (14.29%) devido a falha do enxerto. Uma diferença estatística foi encontrada na análise entre os pacientes que não usaram o ácido ursodesoxicólico, analgésicos opioides ou imunossupressores. A necessidade de um RCTH entre aqueles que usaram estes medicamentos de forma inapropriada foi 16,12, 12,79 e 4,5 vezes maior, respectivamente, do que entre os que as usaram corretamente. Conclusão: houve uma diferença relacionada ao motivo que levou ao retransplante e os indivíduos analisados. A conclusão é que a razão preditiva para retransplante nesta amostra foi a recidiva da doença.

show abstract

“…Immune reconstitution (IR) was important for long-term survivors after allo-HSCT, and patients with poor IR were associated with a higher risk of infections and non-relapse mortality (NRM) ( 18 , 19 ). Active aGVHD could influence IR ( 20 ). In addition, SR-aGVHD patients would receive intensive immunosuppressants, which might show a prolonged negative impact on IR even in those who recovered after therapies.…”

Section: Introductionmentioning

confidence: 99%

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment

et al. 2022

View full text Add to dashboard Cite

We aimed to identify the characteristics of immune reconstitution (IR) in patients who recovered from steroid-refractory acute graft-versus-host disease (SR-aGVHD) after basiliximab treatment. A total of 179, 124, 80, and 92 patients were included in the analysis for IR at 3, 6, 9, and 12 months, respectively, after haploidentical donor hematopoietic stem cell transplantation (HID HSCT). We observed that IR was fastest for monocytes and CD8+ T cells, followed by lymphocytes, CD3+ T cells, and CD19+ B cells and slowest for CD4+ T cells. Almost all immune cell subsets recovered comparably between patients receiving <5 doses and ≥5 doses of basiliximab. Most immune cell subsets recovered comparably between SR-aGVHD patients who recovered after basiliximab treatment and event-free HID HSCT recipients. Patients who recovered from SR-aGVHD after basiliximab treatment experienced satisfactory IR, which suggested that basiliximab may not have prolonged the negative impact on IR in these patients.

show abstract

Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation

Cited by 12 publications

References 135 publications

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Analysis of factors associated with hematopoietic stem-cell retransplantation: a case-control study

Análise dos fatores associados ao retransplante de células-tronco hematopoiéticas: estudo caso-controle

Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment

Contact Info

Product

Resources

About